Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578883 | 0.84 | CYP2D6 (0.49) | CYP2D6TSHRCYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL5578667 | 0.80 | SIGMAR1 (0.47) | CYP2C9LMNAALDH1A1HPGDMEN1 | |
| SCHEMBL25284686 | 0.79 | DRD2 (0.75) | CYP2D6TSHRLMNADRD2ALDH1A1 | |
| SCHEMBL5579055 | 0.77 | SIGMAR1 (0.49) | TSHRLMNADRD2 | |
| SCHEMBL5578645 | 0.77 | SIGMAR1 (0.49) | TSHRUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL25244878 | 0.75 | DRD2 (0.69) | CYP2D6CYP3A4LMNADRD2ALDH1A1 | |
| SCHEMBL18209386 | 0.74 | SIGMAR1 (0.59) | CYP2D6DRD2 | |
| SCHEMBL18221709 | 0.73 | SIGMAR1 (0.67) | CYP2D6TSHRCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL5578836 | 0.73 | SMN1; SMN2 (0.57) | CYP2D6TSHRCYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL25284745 | 0.73 | DRD2 (0.88) | CYP2D6TSHRLMNADRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | CYP2D6 297/4885TSHR 3350/4885CYP3A4 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.